23andMe Holding Co. – NASDAQ:ME
23andMe Holding stock price today
$0.606
-2.69
-81.63%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
23andMe Holding stock price monthly change
+583.37%
month
23andMe Holding stock price quarterly change
+583.37%
quarter
23andMe Holding stock price yearly change
+265.98%
year
23andMe Holding key metrics
Market Cap | 87.59M |
Enterprise value | 639.76M |
P/E | -3.08 |
EV/Sales | 2.07 |
EV/EBITDA | -2.34 |
Price/Sales | 3.22 |
Price/Book | 1.32 |
PEG ratio | 0.06 |
EPS | -1.4 |
Revenue | 219.63M |
EBITDA | -84.70M |
Income | -666.70M |
Revenue Q/Q | -30.68% |
Revenue Y/Y | -26.66% |
Profit margin | -103.07% |
Oper. margin | -105.37% |
Gross margin | 46.01% |
EBIT margin | -105.37% |
EBITDA margin | -38.57% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free23andMe Holding stock price history
23andMe Holding stock forecast
23andMe Holding financial statements
| Jun 2023 | 60.86M | -104.62M | -171.9% |
|---|---|---|---|
| Sep 2023 | 49.99M | -75.27M | -150.54% |
| Dec 2023 | 44.74M | -277.97M | -621.22% |
| Mar 2024 | 64.02M | -208.83M | -326.16% |
| 2026 | 276.13M | -351M | -127.11% |
|---|---|---|---|
| 2027 | 303.24M | -232.02M | -76.51% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-08 | -0.14 | -0.16 |
|---|---|---|
| 2024-02-07 | -0.14 | -0.17 |
| 2024-05-23 | -0.15 | -0.12 |
| Jun 2023 | 871199000 | 195.70M | 22.46% |
|---|---|---|---|
| Sep 2023 | 801230000 | 175.97M | 21.96% |
| Dec 2023 | 608211000 | 231.02M | 37.98% |
| Mar 2024 | 395167000 | 206.64M | 52.29% |
| Jun 2023 | -69.35M | -2.69M | -114K |
|---|---|---|---|
| Sep 2023 | -57.11M | -2.77M | 1.59M |
| Dec 2023 | -12.06M | -2.01M | 105K |
| Mar 2024 | -16.99M | -2.14M | -6.79M |
23andMe Holding alternative data
| Aug 2023 | 769 |
|---|---|
| Sep 2023 | 758 |
| Oct 2023 | 758 |
| Nov 2023 | 758 |
| Dec 2023 | 769 |
| Jan 2024 | 769 |
| Feb 2024 | 769 |
| Mar 2024 | 769 |
| Apr 2024 | 769 |
| May 2024 | 769 |
| Jun 2024 | 769 |
| Jul 2024 | 560 |
23andMe Holding other data
11.15%
-18.78%
of ME is owned by hedge funds
113
-49
50.55M
-84.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 40894 |
| Jul 2023 | 0 | 81788 |
| Aug 2023 | 0 | 81788 |
| Sep 2023 | 0 | 81980 |
| Oct 2023 | 0 | 77096 |
| Nov 2023 | 0 | 115644 |
| Dec 2023 | 0 | 77096 |
| Jan 2024 | 0 | 77096 |
| Feb 2024 | 0 | 77096 |
| Mar 2024 | 0 | 77096 |
| Apr 2024 | 0 | 77096 |
| May 2024 | 0 | 38551 |
| Quarter | Transcript |
|---|---|
| Q4 2024 23 May 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2024 7 Feb 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 8 Nov 2023 | Q2 2024 Earnings Call Transcript |
| Q4 2023 25 May 2023 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Steven J. Schoch (1959) Chief Financial and Accounting Officer | $582,830 |
Ms. Kathy L. Hibbs Esq., J.D. (1964) Chief Legal & Regulatory Officer and Sec. | $558,530 |
| Dr. Kenneth J. Hillan (1961) Head of Therapeutics | $557,620 |
23andMe Holding: At Risk Of Becoming Irrelevant
23andMe Looking Promising For The Long Term
23andMe: Still On The Sidelines
Organigram And Rounding Out My Tax Loss Selling Basket
Adding 23andMe To My Tax Loss Basket
23andMe: Strong Genomics Quarter But Cash Burn Is Huge
23andMe: Disappointing Results Could Mean Potential Acquisition Target
23andMe: Treacherous Path To Profitability
Hims & Hers: Here's A Prescription For Portfolio Dysfunction
-
What's the price of 23andMe Holding stock today?
One share of 23andMe Holding stock can currently be purchased for approximately $0.61.
-
When is 23andMe Holding's next earnings date?
Unfortunately, 23andMe Holding's (ME) next earnings date is currently unknown.
-
Does 23andMe Holding pay dividends?
No, 23andMe Holding does not pay dividends.
-
How much money does 23andMe Holding make?
23andMe Holding has a market capitalization of 87.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 19.22% to 219.64M US dollars. 23andMe Holding made a loss 666.7M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.
-
What is 23andMe Holding's stock symbol?
23andMe Holding Co. is traded on the NASDAQ under the ticker symbol "ME".
-
What is 23andMe Holding's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of 23andMe Holding?
Shares of 23andMe Holding can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 23andMe Holding's key executives?
23andMe Holding's management team includes the following people:
- Mr. Steven J. Schoch Chief Financial and Accounting Officer(age: 66, pay: $582,830)
- Ms. Kathy L. Hibbs Esq., J.D. Chief Legal & Regulatory Officer and Sec.(age: 61, pay: $558,530)
- Dr. Kenneth J. Hillan Head of Therapeutics(age: 64, pay: $557,620)
-
How many employees does 23andMe Holding have?
As Jul 2024, 23andMe Holding employs 560 workers, which is 27% less then previous month and 27% less then previous quarter.
-
When 23andMe Holding went public?
23andMe Holding Co. is publicly traded company for more then 4 years since IPO on 23 Nov 2020.
-
What is 23andMe Holding's official website?
The official website for 23andMe Holding is 23andme.com.
-
Where are 23andMe Holding's headquarters?
23andMe Holding is headquartered at 349 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact 23andMe Holding?
23andMe Holding's mailing address is 349 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 09386300.
23andMe Holding company profile:
23andMe Holding Co.
23andme.comExchange:
NASDAQ
Full time employees:
560
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
349 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001804591
ISIN: US90138Q1085
CUSIP: 90138Q108
